Corrections:

Chengfei Liu¹, Cameron Armstrong¹, Yezi Zhu^1,2, Wei Lou¹ and Allen C. Gao^1,2,3

¹Department of Urology, University of California Davis, CA, USA
²Graduate Program in Pharmacology and Toxicology, University of California Davis, CA, USA
³UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA

Published: October 1, 2024

Copyright: © 2024 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 5E, row H/E, the image in the ‘Abi-Acetate’ panel is an accidental duplicate of the image found in the ‘Control’ panel. The corrected Figure 5E, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:32210–32220. DOI: https://doi.org/10.18632/oncotarget.8493

Figure 5: Niclosamide enhanced abiraterone treatment in vivo. (A) Mice bearing CWR22Rv1 xenografts were treated with vehicle control, abiraterone acetate (200 mg/Kg orally), niclosamide (500 mg/Kg orally) or their combination for 3 weeks, tumor volumes were measured twice every week and the tumors were collected. (B) Pictures of tumors from each group were taken after 3 weeks treatment. (C, D) Each group tumor weight and body weight were measured and averaged. (E) Ki67 was analyzed in tumor tissues by IHC staining and quantified as described in methods. ^*P < 0.05. Abbreviation: Abi-Acetate: Abiraterone Acetate.